This story is republished from STAT, the health and medicine news site that’s a partner to the Globe. Sign up for STAT’s free Morning Rounds newsletter here. Moderna said Wednesday afternoon that its ...
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. A vaccine Moderna has long been developing for the ...
CAMBRIDGE, MA / ACCESS Newswire / October 22, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced topline results from a Phase 3 pivotal trial evaluating the efficacy of mRNA-1647, the Company's ...
Jason Mast is a general assignment reporter at STAT focused on the science behind new medicines and the systems and people that decide whether that science ever reaches patients. You can reach Jason ...
Moderna plans to continue evaluating mRNA-1647 in an ongoing Phase 2 trial for bone marrow transplant patients, where the vaccine could potentially suppress disease associated with CMV reactivation.
JOELTON, Tenn. (WTVF) — I-24 WB near mile marker 34 near Joelton was down to one lane following a crash involving an overturned CMV. The trailer is now upright, and crews are pumping diesel fuel out ...
Oct 22 (Reuters) - Moderna (MRNA.O), opens new tab said on Wednesday it would stop developing its experimental vaccine to prevent cytomegalovirus, a virus that can cause birth defects, after it failed ...
Moderna is halting development of an mRNA vaccine for congenital cytomegalovirus after its candidate failed to protect women from the virus in a large phase 3 trial, the biotech announced in a ...
Moderna has decided to halt the development of its mRNA-1647 vaccine for congenital cytomegalovirus (CMV) infections – once touted as a future blockbuster – after it failed the Phase 3 CMVictory trial ...
In a nation where the smartphone rarely leaves the palm, while the TV’s on in the background, new research from Nielsen Consumer & Media View (CMV) reveals Australians are not abandoning traditional ...
The trial will investigate administering Cytogam after antiviral prophylaxis to reduce late-onset CMV risk in kidney transplant recipients. Credit: sweet_tomato / Shutterstock.com. Kamada has enrolled ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback